logo
Plus   Neg
Share
Email

Merck To Acquire Peloton - Quick Facts

Merck (MRK) has reached an agreement with Peloton Therapeutics, Inc., under which a Merck unit will acquire Peloton for an upfront payment of $1.05 billion. Peloton shareholders will receive a further $1.15 billion on achievement of certain milestones.

Peloton Therapeutics is a clinical-stage biopharmaceutical company focused on the development of small molecule therapeutic candidates for the treatment of patients with cancer and other non-oncology diseases. Peloton's lead candidate PT2977, an oral HIF-2a inhibitor, is in late-stage development for renal cell carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a batch of renewable energy deals totaling 1.6 GW through 18 acquisitions spread across three continents. The deals are intended to "spur the construction of more than $2 billion in new energy infrastructure," the company said. Google said the deals will increase its worldwide portfolio... Beyond Meat's main competitor Impossible Foods will launch its grocery store in California on Friday. Beyond Meat Inc. (BYND), the meatless burger and sausage maker, announced the appointment of Sanjay Shah as Chief Operating Officer. Shah will assume the responsibility for Beyond Meat's global operations and production, effective September 18.
Follow RTT
>